Mn Services Vermogensbeheer B.V. Boosts Position in AbbVie Inc (ABBV)

Mn Services Vermogensbeheer B.V. boosted its stake in shares of AbbVie Inc (NYSE:ABBV) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 262,490 shares of the company’s stock after buying an additional 1,900 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in AbbVie were worth $23,325,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Bristlecone Advisors LLC purchased a new stake in shares of AbbVie during the 3rd quarter valued at $113,000. Acropolis Investment Management LLC purchased a new position in AbbVie in the 2nd quarter worth $106,000. Ffcm LLC raised its stake in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the last quarter. Hudock Capital Group LLC raised its stake in AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the last quarter. Finally, Hershey Trust Co. purchased a new position in AbbVie in the 3rd quarter worth $139,000. Institutional investors own 69.28% of the company’s stock.

A number of brokerages recently issued reports on ABBV. Argus raised their target price on AbbVie from $120.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. BMO Capital Markets lowered AbbVie from a “market perform” rating to an “underperform” rating and reduced their target price for the stock from $125.86 to $84.00 in a research note on Monday, January 29th. They noted that the move was a valuation call. UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Friday, October 13th. Jefferies Group increased their price target on AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a research report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $117.26.

AbbVie Inc (NYSE ABBV) traded down $1.17 during trading hours on Friday, hitting $115.17. The stock had a trading volume of 7,184,173 shares, compared to its average volume of 5,800,000. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc has a 52-week low of $60.05 and a 52-week high of $125.86. The firm has a market cap of $183,590.00, a PE ratio of 27.95, a PEG ratio of 1.11 and a beta of 1.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The company had revenue of $7.74 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same period in the previous year, the firm posted $1.20 EPS. AbbVie’s revenue was up 13.9% compared to the same quarter last year. equities research analysts expect that AbbVie Inc will post 7.46 earnings per share for the current year.

In other AbbVie news, Chairman Richard A. Gonzalez sold 218,193 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares of the company’s stock, valued at approximately $46,255,740.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Severino sold 25,633 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the transaction, the executive vice president now directly owns 114,922 shares in the company, valued at $10,881,964.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 476,376 shares of company stock worth $45,580,873. 0.23% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Mn Services Vermogensbeheer B.V. Boosts Position in AbbVie Inc (ABBV)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/03/mn-services-vermogensbeheer-b-v-grows-position-in-abbvie-inc-abbv.html.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply